Article info
Clinical science
Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy
- Correspondence to Dr Chui Ming Gemmy Cheung, Medical Retina, Singapore National Eye Centre, Singapore, Singapore, Singapore; gemmy.cheung.c.m{at}singhealth.com.sg
Citation
Efficacy of a novel personalised aflibercept monotherapy regimen based on polypoidal lesion closure in participants with polypoidal choroidal vasculopathy
Publication history
- Received November 4, 2020
- Revised January 4, 2021
- Accepted January 26, 2021
- First published February 11, 2021.
Online issue publication
June 28, 2023
Article Versions
- Previous version (28 June 2023).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.